VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Subjects aged 18 years or older, at the time of    │ Subjects aged 18 years or older, at the time of    │     100 │
│ signing the informed consent                       │ signing the informed consent                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects with documented physician diagnosis of    │ Subjects with documented physician diagnosis of    │     100 │
│ asthma as their primary respiratory disease        │ asthma as their primary respiratory disease        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Male or female subjects will be included. A female │ Male or female subjects will be included. A female │     100 │
│ subject is eligible to participate if she is not   │ subject is eligible to participate if she is not   │         │
│ pregnant, not breastfeeding, and at least one of   │ pregnant, not breastfeeding, and at least one of   │         │
│ the following conditions applies: (i) Not a woman  │ the following conditions applies: (i) Not a woman  │         │
│ of childbearing potential (WOCBP). (ii) A WOCBP    │ of childbearing potential (WOCBP). (ii) A WOCBP    │         │
│ who agrees to follow the contraceptive guidance    │ who agrees to follow the contraceptive guidance    │         │
│ during the treatment period and for at least 5     │ during the treatment period and for at least 5     │         │
│ days\] after the last dose of study treatment      │ days] after the last dose of study treatment       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Capable of giving signed informed consent which    │ Capable of giving signed informed consent which    │     100 │
│ includes compliance with the requirements and      │ includes compliance with the requirements and      │         │
│ restrictions listed in the consent form and        │ restrictions listed in the consent form and        │         │
│ protocol                                           │ protocol                                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subject understands and is willing, able, and      │ Subject understands and is willing, able, and      │     100 │
│ likely to comply with study procedures and         │ likely to comply with study procedures and         │         │
│ restrictions                                       │ restrictions                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subject must be able to read in a language         │ Subject must be able to read in a language         │     100 │
│ supported by the smart phone app in their region   │ supported by the smart phone app in their region   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subject must have been on maintenance therapy      │ Subject must have been on maintenance therapy      │     100 │
│ (Fixed dose combination ICS/LABA) for 3 months,    │ (Fixed dose combination ICS/LABA) for 3 months,    │         │
│ cannot have changed dose in the month prior to     │ cannot have changed dose in the month prior to     │         │
│ screening and be able to change to an equivalent   │ screening and be able to change to an equivalent   │         │
│ dose of RELVAR/BREO for the duration of the study. │ dose of RELVAR/BREO for the duration of the study. │         │
│ Other background asthma medication such as anti-   │ Other background asthma medication such as anti-   │         │
│ leukotrienes and oral corticosteroids are          │ leukotrienes and oral corticosteroids are          │         │
│ permitted provided the dose has been stable for 1  │ permitted provided the dose has been stable for 1  │         │
│ month prior to screening                           │ month prior to screening                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subject must be able to change to                  │ Subject must be able to change to                  │     100 │
│ Salbutamol/Albuterol MDI rescue for the duration   │ Salbutamol/Albuterol MDI rescue for the duration   │         │
│ of the study and judged capable of withholding     │ of the study and judged capable of withholding     │         │
│ albuterol/salbutamol for at least 6 hours prior to │ albuterol/salbutamol for at least 6 hours prior to │         │
│ study visits                                       │ study visits                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subject must have their own Android or iPhone      │ Subject must have their own Android or iPhone      │     100 │
│ operating system (IOS) smart phone and a data      │ operating system (IOS) smart phone and a data      │         │
│ package suitable for the installation and running  │ package suitable for the installation and running  │         │
│ of the app and sending and receiving data. Data    │ of the app and sending and receiving data. Data    │         │
│ used by the CIS is approximately 1 megabyte (MB)   │ used by the CIS is approximately 1 megabyte (MB)   │         │
│ per month as a maximum; this is less data than a 1 │ per month as a maximum; this is less data than a 1 │         │
│ minute video streamed from YouTube (2MB)           │ minute video streamed from YouTube (2MB)           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects must be willing and able to download the  │ Subjects must be willing and able to download the  │     100 │
│ app on their personal smart phone and keep it      │ app on their personal smart phone and keep it      │         │
│ turned on for the duration of the study. This will │ turned on for the duration of the study. This will │         │
│ also require Bluetooth to be turned on for         │ also require Bluetooth to be turned on for         │         │
│ duration of the study. Subjects will also have to  │ duration of the study. Subjects will also have to  │         │
│ turn on mobile data for the app for the duration   │ turn on mobile data for the app for the duration   │         │
│ of study; unless travelling and when extra data    │ of study; unless travelling and when extra data    │         │
│ roaming costs could be incurred                    │ roaming costs could be incurred                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects with a known or suspected alcohol or drug │ Subjects with a known or suspected alcohol or drug │     100 │
│ abuse which in the opinion of the investigator     │ abuse which in the opinion of the investigator     │         │
│ could interfere with the subject's proper          │ could interfere with the subject's proper          │         │
│ completion of the protocol requirement             │ completion of the protocol requirement             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of life threatening asthma: Defined as an  │ History of life threatening asthma: Defined as an  │     100 │
│ asthma episode that required intubation and/or was │ asthma episode that required intubation and/or was │         │
│ associated with hypercapnea, respiratory arrest or │ associated with hypercapnea, respiratory arrest or │         │
│ hypoxic seizures within the last 6 months          │ hypoxic seizures within the last 6 months          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ A lower respiratory tract infection within 7 days  │ A lower respiratory tract infection within 7 days  │     100 │
│ of the screening visit                             │ of the screening visit                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Concurrent diagnosis of chronic obstructive        │ Concurrent diagnosis of chronic obstructive        │     100 │
│ pulmonary disease (COPD) or other respiratory      │ pulmonary disease (COPD) or other respiratory      │         │
│ disorders including active tuberculosis, lung      │ disorders including active tuberculosis, lung      │         │
│ cancer, bronchiectasis, sarcoidosis, lung          │ cancer, bronchiectasis, sarcoidosis, lung          │         │
│ fibrosis, pulmonary hypertension, interstitial     │ fibrosis, pulmonary hypertension, interstitial     │         │
│ lung diseases or other active pulmonary diseases   │ lung diseases or other active pulmonary diseases   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of hypersensitivity/intolerance to any     │ History of hypersensitivity/intolerance to any     │     100 │
│ components of the study inhalers (example,         │ components of the study inhalers (example,         │         │
│ lactose, magnesium stearate). In addition,         │ lactose, magnesium stearate). In addition,         │         │
│ subjects with a history of severe milk protein     │ subjects with a history of severe milk protein     │         │
│ allergy that, in the opinion of the study          │ allergy that, in the opinion of the study          │         │
│ physician, contraindicates participation will also │ physician, contraindicates participation will also │         │
│ be excluded                                        │ be excluded                                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Historical or current evidence of clinically       │ Historical or current evidence of clinically       │     100 │
│ significant or rapidly progressing or unstable     │ significant or rapidly progressing or unstable     │         │
│ cardiovascular, neurological, cardiovascular,      │ cardiovascular, neurological, cardiovascular,      │         │
│ neurological, renal, hepatic, immunological,       │ neurological, renal, hepatic, immunological,       │         │
│ endocrine (including uncontrolled diabetes or      │ endocrine (including uncontrolled diabetes or      │         │
│ thyroid disease) or hematological abnormalities    │ thyroid disease) or hematological abnormalities    │         │
│ that are uncontrolled. Significant is defined as   │ that are uncontrolled. Significant is defined as   │         │
│ any disease that, in the opinion of the            │ any disease that, in the opinion of the            │         │
│ investigator, would put the safety of the subject  │ investigator, would put the safety of the subject  │         │
│ at risk through participation, or which would      │ at risk through participation, or which would      │         │
│ affect the analysis if the disease/condition       │ affect the analysis if the disease/condition       │         │
│ exacerbated during the study                       │ exacerbated during the study                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects who have ever received treatment with     │ Subjects who have ever received treatment with     │     100 │
│ biological based therapy example, omalizumab,      │ biological based therapy example, omalizumab,      │         │
│ mepolizumab, for asthma                            │ mepolizumab, for asthma                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects who have received an investigational drug │ Subjects who have received an investigational drug │     100 │
│ and/or medical device within 30 days of entry into │ and/or medical device within 30 days of entry into │         │
│ this study (Screening), or within five drug half-  │ this study (Screening), or within five drug half-  │         │
│ lives of the investigational drug, whichever is    │ lives of the investigational drug, whichever is    │         │
│ longer                                             │ longer                                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ A subject will not be eligible for this study if   │ A subject will not be eligible for this study if   │     100 │
│ he/she is an immediate family member of the        │ he/she is an immediate family member of the        │         │
│ participating investigator, sub-investigator,      │ participating investigator, sub-investigator,      │         │
│ study coordinator, employee of the participating   │ study coordinator, employee of the participating   │         │
│ investigator, or any family member of a Propeller  │ investigator, or any family member of a Propeller  │         │
│ Health employee                                    │ Health employee                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ ACT score \<20 at screening visit                  │ ACT score <20 at screening visit                   │      98 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Non-smokers (never smoked or not smoking for \>6   │ Non-smokers (never smoked or not smoking for >6    │      99 │
│ months with \<10 pack years history (Pack years =  │ months with <10 pack years history (Pack years =   │         │
│ \[cigarettes per day smoked/20\] multiplied by     │ [cigarettes per day smoked/20] multiplied by       │         │
│ number of years smoked)                            │ number of years smoked)                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ ACT score \<20 at randomization visit (visit 2)    │ ACT score <20 at randomization visit (visit 2)     │      99 │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒══════════════════════════════════════╤═════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                    │ CHIA Criteria                                   │   Score │
╞══════════════════════════════════════╪═════════════════════════════════════════════════╪═════════╡
│ Must have minimum age of 18 Years    │ Subjects aged 18 years or older, at the time of │      33 │
│                                      │ signing the informed consent                    │         │
├──────────────────────────────────────┼─────────────────────────────────────────────────┼─────────┤
│ Inclusion criteria for randomization │ ACT score <20 at randomization visit (visit 2)  │      46 │
╘══════════════════════════════════════╧═════════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 99
Average Levenshtein Ratio of individual lines: 94.79166666666667
OverAll Ratio: 96.89583333333334
